Tracleer 'whistleblower' case by the US Department of Justice dismissed

In connection with a qui tam proceeding ("whistleblower case"), Swiss biotech firm Actelion (SIX: ATLN) previously announced in September 2010 that its fully owned US subsidiary Actelion Pharmaceuticals US received a subpoena from the US Attorney's Office for the Northern District of California relating, among other things, to the marketing and sales practices of its leading pulmonary arterial hypertension drug Tracleer (bosentan) in the USA.

Actelion Pharmaceuticals US has now learned that the US Attorney's Office, 27 States and the District of Columbia have declined to intervene in the qui tam action. The qui tam plaintiffs thereafter voluntarily dismissed the case. The case is therefore closed. Actelion made no payment to secure this dismissal.